Clinical Trial Update: Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 trial updating on rifaximin and norfloxacin for preventing spontaneous bacterial peritonitis in adults with decompensated cirrhosis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis Liver

Drugs mentioned

• Norfloxacin (Norfloxacin)
• Rifaximin (rifaximin)

Snippet

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh | Conditions: Cirrhosis, Liver | Phase 3 | Status: COMPLETED